CPX-315 clinical trials

CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

This study compares a new treatment, CPX-351, with standard chemotherapy for people aged 50 and over newly diagnosed with acute myeloid leukaemia (AML) that has certain genetic markers. It aims to see if CPX-351 is more effective.